This Article Full Text Full Text (PDF) All Versions of this Article: 27/4/722    most recent 01.ATV.0000259363.91070.f1v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Howard, E. L. Articles by Becker, R. C. Search for Related Content PubMed PubMed Citation Articles by Howard, E. L. Articles by Becker, R. C. Related Collections Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:722.)
© 2007 American Heart Association, Inc.

Brief Reviews

Factor IXa Inhibitors as Novel Anticoagulants

Emily L. Howard; Kristian C.D. Becker; Christopher P. Rusconi; Richard C. Becker

From the Department of Pathology, Duke University Medical Center, Durham, NC; Department of Chemistry, Boston University, Mass; Regado Biosciences Inc, Durham, NC; and Department of Medicine, Divisions of Cardiology and Hematology, Duke University Medical Center, Durham, NC.

Correspondence to Richard C. Becker, MD, Professor of Medicine, Duke University School of Medicine, Director, Cardiovascular Thrombosis Center, Duke University Medical School, 2400 Pratt St, Durham, NC 27710. E-mail becke021{at}mc.duke.edu

Series Editor: Jeffrey I. Weitz
Emerging Anticoagulant Drugs
ATVB In Focus

Currently available anticoagulants are limited by modest therapeutic benefits, narrow clinical applications, increased bleeding risk, and drug-induced thrombophilia. Because factor IX plays a pivotal role in tissue factor (TF)–mediated thrombin generation, it may represent a promising target for drug development. Several methods of attenuating factor IX activity, including monoclonal antibodies, synthetic active site-blocked competitive inhibitors, oral inhibitors, and RNA aptamers, have undergone investigation. This review summarizes present knowledge of factor IX inhibitors with emphasis on biology, pharmacology, preclinical data, and early-phase clinical experience in humans.

This review summarizes factor IXa inhibitors, an emerging class of anticoagulants that includes active site-blocked inhibitors, monoclonal antibodies, oral inhibitors, and RNA aptamers.

Key Words: anticoagulants • coagulation • factor IX (fIX), monoclonal antibodies (mAb), RNA aptamers

Related Article:

Emerging Anticoagulant Drugs

Jeffrey I. Weitz
Arterioscler. Thromb. Vasc. Biol. 2007 27: 721. [Full Text] [PDF]

This article has been cited by other articles:

				M. Y. Chan, M. G. Cohen, C. K. Dyke, S. K. Myles, L. G. Aberle, M. Lin, J. Walder, S. R. Steinhubl, I. C. Gilchrist, N. S. Kleiman, et al. Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease Circulation, June 3, 2008; 117(22): 2865 - 2874. [Abstract] [Full Text] [PDF]

				J. Hirsh, M. O'Donnell, and J. W. Eikelboom Beyond Unfractionated Heparin and Warfarin: Current and Future Advances Circulation, July 31, 2007; 116(5): 552 - 560. [Full Text] [PDF]